Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
29 juin 2023 06h00 HE
|
Domain Therapeutics
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies DT-7012 nominated based on its...
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities
05 juin 2023 07h00 HE
|
Domain Therapeutics
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities DT-9045 is a unique drug candidate due to its competitive...
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study
05 janv. 2023 02h00 HE
|
Domain Therapeutics
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study EP4R antagonist is Domain...
Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts
08 déc. 2022 01h00 HE
|
Domain Therapeutics
Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts Global key opinion leaders, Professor Antoine Italiano and Professor John Stagg, will join...
Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting
10 nov. 2022 09h00 HE
|
Domain Therapeutics
Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual MeetingData unveiled on clinical candidate EP4R antagonist, DT-9081, and CCR8 depleting-antibody...
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors
19 oct. 2022 01h00 HE
|
Domain Therapeutics
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors Clinical trial applications accepted in France and Belgium for initiation of Phase I clinical...
Domain Therapeutics to present new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting
06 oct. 2022 01h00 HE
|
Domain Therapeutics
Domain Therapeutics to present new data on its EP4R and CCR8 antagonists at 2022 SITC Annual Meeting Domain will present two posters on its clinical candidate EP4R antagonist, DT-9081, ...